Novavax takes a beating on the stock exchange after FDA approval
Earlier this week, Novavax made a deal with the US authorities for 3.2 million vaccine doses, subject to the vaccine’s approval. Despite Wednesday’s approval, the firm has been nosediving on the stock exchange.
by marketwire, translated by daniel pedersen
Following Thursday’s news that Novavax had finally received the sought-after emergency authorization for its Covid-19 vaccine from the US Food and Drug Administration (FDA), the firm dropped 25.1% on the stock exchange.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novavax vaccine recommended for approval for EU teenagers
For subscribers
